A nutraceutical rich in DHA improves portal hypertension in cirrhosis

3 October, 2019

Barcelona Liver Bioservices announced today the publication of the manuscript entitled “A nutraceutical rich in docosahexaenoic acid improves portal hypertension in a preclinical model of advanced chronic liver disease” in the peer-reviewed journal Nutrients.

 

Barcelona Liver Bioservices (BLB), CRO specialized in liver diseases, announced today the publication of the manuscript entitled “A nutraceutical rich in docosahexaenoic acid improves portal hypertension in a preclinical model of advanced chronic liver disease” in the peer-reviewed journal Nutrients. The study describes the pre-clinical research developed in collaboration with BrudyLab, biotech company specialized in the development and commercialization of molecules derived from omega-3 fatty acid.

 

“The study demonstrates the beneficial effects of BrudyLab’s unique DHA formulation improving the hepatic fatty acid profile, portal pressure, inflammation and hepatic stellate cells phenotype in pre-clinical models of advanced chronic liver disease” summarizes Zoe Boyer, Associate Scientist at BLB and first author of the manuscript.

 

According to BLB & BrudyLab partnership, both entities will continue working together to further understand the underlying mechanisms of Brudy’s patent-protected compound while exploring possibilities to offer it to patients with chronic liver disease. “We very much look forward to continuing working with BrudyLab, due to its antioxidant properties their DHA formulation has high potential as nutraceutical supplement for liver diseases. Particularly, its benefits on fatty acid profile, inflammation and portal hypertension suggest high applicability for the treatment of NASH” stated Dr Jaime Bosch, vice-president of clinical research at BLB.

 

View full article

 

Barcelona Liver Bioservices is a CRO focused on the design and development of pre-clinical research in the field of Hepatology. The company offers cutting-edge research services and consulting to foster the development of new therapeutics for liver diseases, including non-alcoholic steatohepatitis and cirrhosis.